Per accedir als documents amb el text complet, si us plau, seguiu el següent enllaç: http://hdl.handle.net/2445/122308
dc.contributor.author | Soto, Marcelo |
---|---|
dc.contributor.author | Sampietro-Colom, Laura |
dc.contributor.author | Lasalvia, Luis |
dc.contributor.author | Mira, Aurea |
dc.contributor.author | Jiménez Povedano, Wladimiro |
dc.contributor.author | Navasa, Miquel |
dc.date | 2018-05-11T13:27:24Z |
dc.date | 2018-05-11T13:27:24Z |
dc.date | 2017-05-07 |
dc.date | 2018-05-11T13:27:24Z |
dc.identifier | 1007-9327 |
dc.identifier | 672060 |
dc.identifier | 28533673 |
dc.identifier.uri | http://hdl.handle.net/2445/122308 |
dc.description | AIM: To assess liver fibrosis (LF) in hepatitis C virus (HCV) and alcoholic liver disease (ALD), estimate health outcomes and costs of new noninvasive testing strategies. METHODS: A Markov model was developed to simulate LF progression in HCV and ALD for a cohort of 40-year-old men with abnormal levels of transaminases. Three different testing alternatives were studied: a single liver biopsy; annual Enhanced liver fibrosis (ELF ) followed by liver stiffness measurement (LSM) imaging as a confirmation test if the ELF test is positive; and annual ELF test without LSM. The analysis was performed from the perspective of a university hospital in Spain. Clinical data were obtained from published literature. Costs were sourced from administrative databases of the hospital. Deterministic and probabilistic sensitivity analyses were performed RESULTS: In HCV patients, annual sequential ELF test/LSM and annual ELF test alone prevented respectively 12.9 and 13.3 liver fibrosis-related deaths per 100 persons tested, compared to biopsy. The incremental cost-effectiveness ratios (ICERs) were respectively 13400 and 11500 per quality-adjusted life year (QALY). In ALD, fibrosis-related deaths decreased by 11.7 and 22.1 per 100 persons tested respectively with sequential ELF test/LSM and annual ELF test alone. ICERs were 280 and 190 per QALY, respectively. CONCLUSION: The use of the ELF test with or without a confirmation LSM are cost-effective options compared to a single liver biopsy for testing liver fibrosis in HCV and ALD patients in Spain. |
dc.format | 11 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Baishideng Publishing Group |
dc.relation | Reproducció del document publicat a: https://doi.org/10.3748/wjg.v23.i17.3163 |
dc.relation | World Journal of Gastroenterology, 2017, vol. 23, num. 17, p. 3163-3173 |
dc.relation | https://doi.org/10.3748/wjg.v23.i17.3163 |
dc.rights | cc-by-nc (c) Soto, Marcelo et al., 2017 |
dc.rights | http://creativecommons.org/licenses/by-nc/3.0/es |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Hepatitis C |
dc.subject | Malalties del fetge |
dc.subject | Hepatitis C |
dc.subject | Liver diseases |
dc.title | Cost-effectiveness of nehanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |